Who makes GLPG2737 single dose?

GLPG2737 single dose is developed by Galapagos NV.

What development phase is GLPG2737 single dose in?

GLPG2737 single dose is in Phase 1.

Last reviewed 2026-04-19 · How we verify

GLPG2737 single dose

Galapagos NV · Phase 1 active Small molecule

At a glance

Generic name	GLPG2737 single dose
Sponsor	Galapagos NV
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. (PHASE1)
Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis (PHASE1)
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GLPG2737 single dose CI brief — competitive landscape report
GLPG2737 single dose updates RSS · CI watch RSS
Galapagos NV portfolio CI